NASDAQ:HRTX Heron Therapeutics Q3 2026 Earnings Date & Estimates $0.41 +0.05 (+13.37%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$0.40 0.00 (-0.52%) As of 10/9/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Heron Therapeutics is scheduled to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 3, 2026TimeBefore Market OpensConference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Heron Therapeutics in Q3 2026Heron Therapeutics is expected to post earnings of -$0.03 per share on revenue of $37.50 million. In the same quarter a year earlier Heron Therapeutics reported -$0.05 per share on revenue of $38.21 million. Heron Therapeutics last reported on August 10, 2026, posting -$0.03 per share and missing the -$0.0050 consensus estimate. Heron Therapeutics has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.03Expected Revenue$37.50 millionPrior-Year EPS-$0.05Prior-Year Revenue$38.21 millionExpected Revenue Growth-1.9%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.03 (Missed by -$0.0250)Last Quarter Revenue$37.67 millionEPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Heron Therapeutics Q3 2026 Earnings FAQ When does Heron Therapeutics report Q3 2026 earnings? Heron Therapeutics (NASDAQ:HRTX) is scheduled to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. What time is Heron Therapeutics' Q3 2026 earnings call? Heron Therapeutics' Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Heron Therapeutics? Analysts expect Heron Therapeutics to post earnings of -$0.03 per share for Q3 2026. How much revenue is Heron Therapeutics expected to report? The consensus revenue estimate for Heron Therapeutics is $37.50 million for Q3 2026. Heron Therapeutics Earnings HeadlinesHead-To-Head Survey: Perrigo (NYSE:PRGO) & Heron Therapeutics (NASDAQ:HRTX)October 8 at 4:59 AM | americanbankingnews.comHRTX Pro Research (inglés)September 30, 2026 | es.investing.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 10 at 1:00 AM | Banyan Hill Publishing (Ad)Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Consensus Rating of "Hold" from BrokeragesSeptember 30, 2026 | americanbankingnews.comHeron Therapeutics firma un accordo di licenza multi-prodotto con Long GroveSeptember 29, 2026 | it.investing.comHeron (HRTX) Q2 2026 Earnings Call TranscriptAugust 17, 2026 | finance.yahoo.comSee More Heron Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Heron Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Heron Therapeutics and other key companies, straight to your email. Email Address About Heron TherapeuticsHeron Therapeutics (NASDAQ:HRTX) is a commercial-stage biotechnology company focused on developing and commercializing medicines for acute care and oncology-related supportive care. The company’s products are designed to address patient needs in areas such as postsurgical pain and chemotherapy-induced nausea and vomiting. Heron’s portfolio includes ZYNRELEF, an extended-release solution combining bupivacaine and meloxicam for the management of postsurgical pain, and APONVIE, an injectable formulation of aprepitant used to help prevent postoperative nausea and vomiting. The company also markets CINVANTI, an intravenous formulation of aprepitant used as part of regimens to prevent chemotherapy-induced nausea and vomiting. Heron’s marketed products are primarily commercialized in the United States through healthcare providers and institutions. The company is headquartered in San Diego, California, and has historically focused its research, development and commercialization activities on therapies intended to improve outcomes and experiences for patients undergoing surgery or cancer treatment.View Heron Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
